Guggenheim keeps USD 20 target for Zura Bio stock before trial data

Published on 10/15/2026 at 12:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Guggenheim kept its USD 20 target on October 7, 2026. Zura Bio stock costs EUR 4.00 at Lang & Schwarz on October 15, 2026, ahead of data from 247 patients.

Trial timing and analyst conviction

Guggenheim reaffirmed a USD 20.00 target on October 7, 2026.
TibuSHIELD is expected to deliver topline data in the fourth quarter of 2026.
Zura Bio stock trades at EUR 4.00 at 12:43 p.m. CEST at Lang & Schwarz on October 15, 2026.
The company reported a USD 26.30 million GAAP net loss for the quarter ended June 30, 2026.

ZURA, KYG9TY5A1016, Illustration mit AI erstellt.

Zura Bio (ISIN KYG9TY5A1016) was trading at EUR 4.00 at Lang & Schwarz on October 15, 2026 at 12:43 p.m. CEST. On October 7, 2026, Guggenheim reaffirmed a Buy rating and a USD 20.00 price target ahead of Zura Bio's TibuSHIELD Phase 2 readout, as Yahoo Finance reported.

Analyst target meets a clinical catalyst

The USD 20.00 target is tied to tibulizumab, an IL-17A and BAFF bispecific antibody being tested in hidradenitis suppurativa. Guggenheim identified the 16-week TibuSHIELD topline results as a key catalyst and expects the readout in the fourth quarter of 2026, according to Yahoo Finance.

What does the pipeline mean?

The trial enrolled 247 patients, giving the upcoming result a defined clinical scale. Zura Bio also lists a Phase 2 systemic sclerosis study and a planned polymyalgia rheumatica study, with NEXUS-PMR expected to begin by year-end 2026, according to the company's investor-relations page at Zura Bio.

Three milestones shape the setup

On August 11, 2026, Zura Bio listed second-quarter financial results among its recent corporate updates. On August 12, 2026, Wedbush raised its target from USD 15.00 to USD 22.00, while Guggenheim raised its target from USD 15.00 to USD 20.00, according to MarketBeat. The October 7, 2026 Guggenheim reaffirmation is the latest of those analyst milestones.

Dates investors can measure

The next stated development is the TibuSHIELD topline readout in the fourth quarter of 2026. The planned NEXUS-PMR Phase 2 study is scheduled to begin by year-end 2026, according to Zura Bio.

Losses keep valuation tied to data

Zura Bio reported a quarterly GAAP net loss of USD 26.30 million for the quarter ended June 30, 2026, compared with USD 15.99 million in the year-earlier quarter, according to Markets Insider. That result leaves the clinical readout as the central valuation test while the company advances several programs.

Stock price and clinical timing

Zura Bio's primary listing is Nasdaq, where the stock was last quoted at USD 4.41 on October 14, 2026 at 4:00 p.m. ET, according to the finance quote. MarketWatch showed a USD 3.15 to USD 7.44 52-week range and a USD 405.36 million market capitalization on October 14, 2026. The Nasdaq-listed stock was trading at EUR 4.00 at Lang & Schwarz on October 15, 2026 at 12:43 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Zura Bio stock.